文献速递头颈与中枢神经肿瘤

鼻咽癌序贯化疗放疗对比诱导化疗联合同期化疗放疗:一项随机临床试验

Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-07-24

这项多中心、开放标签、3期非劣效随机临床试验于2018年1月至2021年9月在中国6家中心纳入420例Ⅲ/ⅣA期鼻咽癌患者,比较序贯化疗放疗(诱导化疗后单纯放疗再辅助化疗)与诱导化疗联合同期化疗放疗。中位随访50个月,3年无失败生存率分别为83.7%与79.5%(HR 0.77,95%CI 0.50-1.19),序贯组3级及以上急性非血液学毒性更低。

要点

  • 序贯组3年无失败生存率83.7%,诱导联合同期组79.5%,HR 0.77(95%CI 0.50-1.19),非劣效成立
  • 序贯组3级及以上急性口腔黏膜炎29.0%,低于诱导联合同期组的41.9%(P<.001)
  • 两组晚期毒性无差异

核心结论

  • 作者认为,在局部晚期鼻咽癌中,序贯化疗放疗在3年无失败生存率方面非劣效于诱导化疗联合同期化疗放疗,且严重急性非血液学毒性更少。

研究设计与样本

  • 多中心、开放标签、3期非劣效随机临床试验,2018年1月至2021年9月在中国6家中心开展,纳入18至65岁新诊断Ⅲ/ⅣA期鼻咽癌患者,按1:1随机分为序贯组210例与诱导联合同期组210例,数据截止日期为2024年6月30日。

主要发现

  • 意向治疗人群中,序贯组3年无失败生存率为83.7%(95%CI 78.6-88.8),诱导联合同期组为79.5%(95%CI 74.0-85.0),HR 0.77(95%CI 0.50-1.19;P=.24),95%CI上限小于1.6;符合方案人群结果相同。
  • 序贯组3级及以上急性口腔黏膜炎61例(29.0%),诱导联合同期组88例(41.9%),P<.001;恶心20例(9.5%)对38例(18.1%),P=.01;呕吐8例(3.8%)对20例(9.5%),P=.02;两组晚期毒性无差异。

关键数值与推荐

  • 主要终点为3年无失败生存率,非劣效界值为10%(风险比小于1.6),以及放疗期间3级及以上急性口腔黏膜炎发生率。
  • 诱导化疗为吉西他滨1000 mg/m2第1、8天联合顺铂25 mg/m2第1、2、3天,每3周重复,共2周期;序贯组后续单纯放疗再2周期辅助化疗(GP方案);诱导联合同期组后续放疗同步每周顺铂30 mg/m2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) has been a standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) but with high acute toxic effects in CCRT phase. Whether CCRT can be safely replaced by radiation therapy with adjuvant chemotherapy (AC) is unknown. OBJECTIVE: To assess if sequential chemoradiotherapy (SCRT; IC, followed by radiotherapy alone, followed by AC) is noninferior to IC plus CCRT for LA-NPC in terms of efficacy, with less acute toxic effects. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, phase 3 noninferiority randomized clinical trial was conducted from January 2018 to September 2021 in 6 centers in China. Patients aged 18 to 65 years with newly diagnosed stage III/IVA NPC were enrolled. The data cutoff date was June 30, 2024. INTERVENTIONS: Patients were randomly assigned 1:1 to receive 2 cycles of IC with a gemcitabine and cisplatin (GP) regimen (gemcitabine, 1000 mg/m2, on days 1 and 8 plus cisplatin, 25 mg/m2, on days 1, 2, and 3, repeated every 3 weeks) plus radiotherapy alone, followed by 2 cycles of AC with a GP regimen (SCRT group) or 2 cycles IC (GP regimen) followed by radiotherapy concurrent with weekly cisplatin, 30 mg/m2 (IC plus CCRT group). MAIN OUTCOMES AND MEASURES: The primary end points were 3-year failure-free survival (FFS) with a noninferiority margin of 10% (hazard ratio [HR] less than 1.6) and the incidence of grade 3 or higher acute mucositis during radiotherapy. The secondary end points included overall survival, locoregional FFS, distant FFS, response rate, and toxic effects. RESULTS: Of 420 enrolled patients, 107 (25.5%) were women, and the median (IQR) age was 48 (41-54) years. A total of 210 patients were randomized to the SCRT group and 210 to the IC plus CCRT group. The median (IQR) follow-up time was 50 (40-61) months. In the intention-to-treat population, 3-year FFS was 83.7% (95% CI, 78.6-88.8) vs 79.5% (95% CI, 74.0-85.0) in the SCRT group vs the IC plus CCRT group, respectively (HR, 0.77; 95% CI, 0.50-1.19; P = .24), with the upper bound of the 95% CI less than 1.6. Identical outcomes were reported in the per-protocol population. Compared with the IC plus CCRT group, the SCRT group had significantly lower incidences of grade 3 or higher acute nonhematological toxic effects (acute mucositis, 61 [29.0%] vs 88 [41.9%], respectively; P < .001; nausea, 20 [9.5%] vs 38[18.1%], respectively; P = .01; vomiting, 8 [3.8%] vs 20 [9.5%], respectively; P = .02). No differences were observed in late toxic effects. CONCLUSIONS AND RELEVANCE: Results from this noninferiority randomized clinical trial suggest that SCRT is noninferior to IC plus CCRT in terms of 3-year FFS in LA-NPC, with less severe acute nonhematological toxic effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03366415.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Xue F, Ou D, Xie C, et al. Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40705321. doi:10.1001/jamaoncol.2025.2191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。